Which organ metabolizes trazodone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Trazodone Metabolism

Trazodone is metabolized primarily in the liver by cytochrome P450 enzymes, particularly CYP3A4. 1

Primary Metabolic Pathway

The liver is the principal organ responsible for trazodone metabolism. CYP3A4 is the dominant enzyme mediating trazodone biotransformation, particularly in the formation of its only pharmacologically active metabolite, m-chlorophenylpiperazine (mCPP) 1, 2. This has been definitively established through multiple lines of evidence:

  • In vitro studies using human liver microsomes demonstrate that mCPP formation correlates significantly only with CYP3A4 activity 2
  • Microsomes from cells expressing individual human cytochrome P450 enzymes show that only CYP3A4 produces mCPP from trazodone 2
  • The CYP3A4 inhibitor ketoconazole potently inhibits mCPP formation in a concentration-dependent manner 2, 3

Additional Metabolic Contributions

While CYP3A4 is the primary enzyme, other cytochrome P450 isoforms contribute to trazodone metabolism through alternative pathways:

  • CYP2D6 participates in the formation of other major inactive metabolites 4
  • CYP2C19 contributes to additional metabolic pathways 4
  • Flavin-containing monooxygenases (FMOs) are involved in forming certain inactive metabolites 4

Clinical Implications

Trazodone undergoes extensive hepatic metabolism, with less than 1% excreted unchanged in urine 1. This extensive first-pass metabolism means:

  • Patients with hepatic impairment may have altered drug clearance
  • Drug interactions with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, certain HIV protease inhibitors) can significantly increase trazodone levels 5, 3
  • Dose adjustment may be needed when trazodone is co-administered with strong CYP3A4 inhibitors 5

The protein binding is high (89-95%), and the drug demonstrates biphasic elimination with a redistribution half-life of approximately one hour and an elimination half-life of 10-12 hours 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.